Production (Stage)
Citius Pharmaceuticals, Inc.
CTXR
$0.703
-$0.021-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.49M | 7.91M | 8.14M | 7.87M | 7.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.26M | 10.04M | 11.05M | 10.63M | 10.97M |
| Operating Income | -11.26M | -10.04M | -11.05M | -10.63M | -10.97M |
| Income Before Tax | -11.25M | -10.02M | -10.93M | -10.43M | -8.40M |
| Income Tax Expenses | 264.20K | 264.20K | 144.00K | 144.00K | 144.00K |
| Earnings from Continuing Operations | -11.51M | -10.28M | -11.08M | -10.57M | -8.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 595.00K | 513.00K | 287.00K | -- | -- |
| Net Income | -10.92M | -9.77M | -10.79M | -10.57M | -8.54M |
| EBIT | -11.26M | -10.04M | -11.05M | -10.63M | -10.97M |
| EBITDA | -11.26M | -10.04M | -11.05M | -10.63M | -10.97M |
| EPS Basic | -1.27 | -1.30 | -1.59 | -1.57 | -1.34 |
| Normalized Basic EPS | -0.75 | -0.77 | -0.90 | -0.94 | -1.06 |
| EPS Diluted | -1.27 | -1.30 | -1.70 | -1.57 | -1.34 |
| Normalized Diluted EPS | -0.75 | -0.77 | -0.90 | -0.94 | -1.06 |
| Average Basic Shares Outstanding | 8.58M | 7.49M | 7.23M | 6.95M | 6.36M |
| Average Diluted Shares Outstanding | 8.58M | 7.49M | 7.23M | 6.95M | 6.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |